Celltrion Files Petition for IPR on Biogen’s Rituximab Patent


Yesterday, Celltrion filed a petition for inter partes review of Biogen’s U.S. Patent No. 7,820,161, which is directed to the use of rituximab to treat rheumatoid arthritis.  We will continue to monitor and report on updates for IPR2016-01614 and will post key documents on our IPR tracker page.

Download PDF

Tagged with 

Comments are closed.